63 active trials 37 recruiting 7 Phase 3 51 sponsors 4 changes in 30 days
| Early Phase 1 | 1 | |
| Phase 1 | 4 | |
| Phase 1/2 | 7 | |
| Phase 2 | 5 | |
| Phase 2/3 | 4 | |
| Phase 3 | 3 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT07609108 | Pridopidine Phase 3 Study in Huntington's Disease | Prilenia | Recruiting | 2026-09-30 |
| NCT07326709 | A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants… | Novartis Pharmaceuticals | Recruiting | 2026-09-22 |
| NCT06312189 | Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With… | Neurocrine Biosciences | Enrolling by Invitation | 2026-06-18 |
| Phase 2/3 | ||||
| NCT07378644 | Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants… | Skyhawk Therapeutics, Inc. | Recruiting | 2026-09-21 |
| NCT04713982 | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | Vanderbilt University Medical Center | Active, Not Recruiting | 2026-08-05 |
| NCT07537075 | An Extension of SKY-0515 in Participants With Huntington's Disease | Skyhawk Therapeutics, Inc. | Enrolling by Invitation | 2026-07-24 |
| NCT06873334 | Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With… | Skyhawk Therapeutics, Inc. | Active, Not Recruiting | 2026-05-01 |
| Phase 2 | ||||
| NCT06853743 | The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside… | Oslo University Hospital | Recruiting | 2025-03-19 |
| NCT05509153 | A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin… | Western Sydney Local Health District | Recruiting | 2025-02-28 |
| NCT04478734 | Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Recruiting | 2025-02-25 |
| NCT05686551 | GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen… | Hoffmann-La Roche | Active, Not Recruiting | 2026-08-10 |
| NCT06254482 | An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in… | Novartis Pharmaceuticals | Active, Not Recruiting | 2025-11-21 |
| Phase 1/2 | ||||
| NCT05822908 | A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD | Vico Therapeutics B. V. | Recruiting | 2026-08-19 |
| NCT06826612 | A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease | Hoffmann-La Roche | Recruiting | 2026-05-05 |
| NCT07451613 | Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease | Leslie Thompson | Recruiting | 2026-04-13 |
| NCT05541627 | A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest… | AskBio France, SAS, a subsidiary of AskBio Inc. | Active, Not Recruiting | 2026-05-14 |
| NCT07339514 | A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest… | ExoRNA Bioscience | Active, Not Recruiting | 2026-01-14 |
| NCT04120493 | Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest… | UniQure Biopharma B.V. | Active, Not Recruiting | 2025-10-21 |
| NCT05243017 | Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease | UniQure Biopharma B.V. | Active, Not Recruiting | 2025-03-10 |
| Phase 1 | ||||
| NCT06585449 | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | Alnylam Pharmaceuticals | Recruiting | 2026-09-16 |
| NCT07536061 | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's… | Sarepta Therapeutics, Inc. | Recruiting | 2026-09-04 |
| NCT07246941 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of… | Hoffmann-La Roche | Active, Not Recruiting | 2026-09-02 |
| NCT07516899 | Mass Balance Study of [14C] LPM3770164 in Healthy Participants | Luye Pharma Group Ltd. | Not Yet Recruiting | 2026-04-08 |
| Early Phase 1 | ||||
| NCT06634628 | iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand… | CHDI Foundation, Inc. | Recruiting | 2026-03-13 |
| Not applicable | ||||
| NCT07513844 | Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in… | First Affiliated Hospital of Fujian Medical University | Recruiting | 2026-04-29 |
Assistance Publique - Hôpitaux de Paris (3) · Hoffmann-La Roche (3) · Skyhawk Therapeutics, Inc. (3) · CHDI Foundation, Inc. (2) · Novartis Pharmaceuticals (2) · UniQure Biopharma B.V. (2) · Universitaire Ziekenhuizen KU Leuven (2) · University Hospital, Angers (2) · University of Central Florida (2) · Alnylam Pharmaceuticals (1)